Nerve Repair and Regeneration Market worth $ 10.59 Billion by 2022

The Nerve Repair and Regeneration Market is expected to reach USD 10.59 Billion by 2022 from USD 5.79 Billion in 2017, at a CAGR of 12.9%. Increasing number of neurological disorders, rising geriatric population, and technological advancements are the major factors that are driving the growth of this market.

Major Market Developments:-

• In June 2015, Boston Scientific launched precision novi spinal cord stimulator system in Europe and received CE Mark approval for it
• In January 2016, Polyganics (the Netherlands) signed an agreement with MicroAire Surgical Instruments (US) to distribute its peripheral nerve repair products in the US and Canada
• In January 2017, Abbott Laboratories acquired St. Jude Medical to strengthen its position in the neuromodulation market
• In September 2017, Medtronic (Ireland) received FDA approval Intellis platform spinal cord stimulator (SCS)
• In May 2015, Axogen (US) received FDA approval for Avance nerve graft

Market Drivers:-

• High incidence of nerve injuries and growing prevalence of neurological disorder
• Increase in geriatric population and subsequent growth in the prevalence of neurological disorder
• Technological advancement

Regional Analysis:-

By region, the nerve repair and regeneration market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by North America, followed by Europe; however, the Asian region is expected to witness the highest growth during the forecast period. The presence of emerging economies like China and India; large population; growth in the number of hospitals, and increasing neurological disorders in the region are some of the key factors driving the high growth of this regional segment.

Read more: - https://www.marketsandmarkets.com/PressReleases/nerve-repair-regeneration.asp

Top key Players:-

Some of the major players operating in the nerve repair and regeneration market are AxoGen (US), Baxter (US), Boston Scientific (US), LivaNova (UK), Integra LifeSciences (US), Medtronic (US), Abbott Laboratories (US), Stryker (US), Nevro (US), Polyganics (Netherlands), and Nuvectra (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.